{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T18:14:09Z","timestamp":1751480049910},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,10,2]],"date-time":"2010-10-02T00:00:00Z","timestamp":1285977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s11894-010-0145-9","type":"journal-article","created":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T05:34:14Z","timestamp":1285911254000},"page":"479-484","source":"Crossref","is-referenced-by-count":13,"title":["The Status of Diagnostic Markers for Inflammatory Bowel Disease"],"prefix":"10.1007","volume":"12","author":[{"given":"Poonam","family":"Beniwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Harrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,10,2]]},"reference":[{"key":"145_CR1","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3748\/wjg.v13.i19.2727","volume":"13","author":"M Papp","year":"2007","unstructured":"Papp M, Norman GL, Altorjay I, Lakatos PL: Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol 2007, 13:2028\u20132036.","journal-title":"World J Gastroenterol"},{"key":"145_CR2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.297.6656.1105","volume":"297","author":"J Main","year":"1988","unstructured":"Main J, McKenzie H, Yeaman GR, et al.: Antibody to Saccharomyces cerevisiae (baker\u2019s yeast) in Crohn\u2019s disease. BMJ 1988, 297:1105\u20131106.","journal-title":"BMJ"},{"key":"145_CR3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0091-6749(05)80067-3","volume":"86","author":"A Saxon","year":"1990","unstructured":"Saxon A, Shanahan F, Landers C, et al.: A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990, 86:202\u2013210.","journal-title":"J Allergy Clin Immunol"},{"key":"145_CR4","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/gut.33.5.668","volume":"33","author":"G Cambridge","year":"1992","unstructured":"Cambridge G, Rampton DS, Stevens TR, et al.: Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1992, 33:668\u2013674.","journal-title":"Gut"},{"key":"145_CR5","first-page":"42","volume":"8","author":"L Harrell","year":"2007","unstructured":"Harrell L: Evolving serological markers for IBD. Inflamm Bowel Dis Monit 2007, 8:42\u201348.","journal-title":"Inflamm Bowel Dis Monit"},{"key":"145_CR6","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1111\/j.1572-0241.2006.00840.x","volume":"101","author":"GE Reese","year":"2006","unstructured":"Reese GE, Constantinides VA, Simillis C, et al.: Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 2006, 101:2410\u20132422.","journal-title":"Am J Gastroenterol"},{"key":"145_CR7","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1053\/gast.2002.32980","volume":"122","author":"S Joossens","year":"2002","unstructured":"Joossens S, Reinisch W, Vermeire S, et al.: The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002, 122:1242\u20131247.","journal-title":"Gastroenterology"},{"key":"145_CR8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s10350-007-9158-3","volume":"51","author":"GY Melmed","year":"2008","unstructured":"Melmed GY, Fleshner P, Bardakcioglu O, et al.: Family history and serology predict Crohn\u2019s disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2008, 51:100\u2013108.","journal-title":"Dis Colon Rectum"},{"key":"145_CR9","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s10350-005-0013-0","volume":"48","author":"T Hui","year":"2005","unstructured":"Hui T, Landers C, Vasiliauskas E, et al.: Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum 2005, 48:1254\u20131262.","journal-title":"Dis Colon Rectum"},{"key":"145_CR10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1191\/0961203306lu2331oa","volume":"15","author":"N Dotan","year":"2006","unstructured":"Dotan N, Altstock RT, Schwarz M, Dukler A: Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus 2006, 15:442\u2013450.","journal-title":"Lupus"},{"key":"145_CR11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1053\/j.gastro.2006.04.030","volume":"131","author":"I Dotan","year":"2006","unstructured":"Dotan I, Fishman S, Dgani Y, et al.: Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn\u2019s disease. Gastroenterology 2006, 131:366\u2013378.","journal-title":"Gastroenterology"},{"key":"145_CR12","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/gut.2006.108043","volume":"56","author":"M Ferrante","year":"2007","unstructured":"\u2022 Ferrante M, Henckaerts L, Joossens M, et al.: New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56:1394\u20131403. This large study examined the association of the newer antiglycan markers and IBD, and was also the first to explore their relationship with complicated disease behavior.","journal-title":"Gut"},{"key":"145_CR13","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ajg.2009.79","volume":"104","author":"CH Seow","year":"2009","unstructured":"Seow CH, Stempak JM, Xu W, et al.: Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol 2009, 104:1426\u20131434.","journal-title":"Am J Gastroenterol"},{"key":"145_CR14","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1172\/JCI200420295","volume":"113","author":"MJ Lodes","year":"2004","unstructured":"Lodes MJ, Cong Y, Elson CO, et al.: Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004, 113:1296\u20131306.","journal-title":"J Clin Invest"},{"key":"145_CR15","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1053\/j.gastro.2005.03.046","volume":"128","author":"SR Targan","year":"2005","unstructured":"Targan SR, Landers CJ, Yang H, et al.: Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn\u2019s disease. Gastroenterology 2005, 128:2020\u20132028.","journal-title":"Gastroenterology"},{"key":"145_CR16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1053\/gast.2000.8519","volume":"119","author":"CL Sutton","year":"2000","unstructured":"Sutton CL, Kim J, Yamane A, et al.: Identification of a novel bacterial sequence associated with Crohn\u2019s disease. Gastroenterology 2000, 119:23\u201331.","journal-title":"Gastroenterology"},{"key":"145_CR17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.MIB.0000218765.84087.42","volume":"12","author":"S Iltanen","year":"2006","unstructured":"Iltanen S, Tervo L, Halttunen T, et al.: Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD. Inflamm Bowel Dis 2006, 12:389\u2013394.","journal-title":"Inflamm Bowel Dis"},{"key":"145_CR18","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1128\/IAI.68.3.1542-1548.2000","volume":"68","author":"O Cohavy","year":"2000","unstructured":"Cohavy O, Bruckner D, Gordon LK, et al.: Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000, 68:1542\u20131548.","journal-title":"Infect Immun"},{"key":"145_CR19","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1111\/j.1572-0241.2004.40369.x","volume":"99","author":"A Zholudev","year":"2004","unstructured":"Zholudev A, Zurakowski D, Young W, et al.: Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn\u2019s disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004, 99:2235\u20132241.","journal-title":"Am J Gastroenterol"},{"key":"145_CR20","doi-asserted-by":"crossref","unstructured":"Garc\u00eda S\u00e1nchez Mdel V, Gonz\u00e1lez R, Iglesias Flores E, et al.: Diagnostic value of fecal calprotectin in predicting an abnormal colonoscopy. Med Clin (Barc) 2006, 127:41\u201346.","DOI":"10.1157\/13090002"},{"key":"145_CR21","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3109\/00365529309098312","volume":"28","author":"AG R\u00f8seth","year":"1993","unstructured":"R\u00f8seth AG, Kristinsson J, Fagerhol MK, et al.: Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993, 28:1073\u20131076.","journal-title":"Scand J Gastroenterol"},{"key":"145_CR22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/gut.2008.170019","volume":"58","author":"D Foell","year":"2009","unstructured":"\u2022 Foell D, Wittkowski H, Roth J: Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut 2009, 58:859\u2013868. This article is a nice review of fecal markers and their role in monitoring disease activity in patients with IBD. This paper also reviews the biology of biomarkers and discusses newer markers on the horizon.","journal-title":"Gut"},{"key":"145_CR23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1590\/S1807-59322009000500009","volume":"64","author":"M Erbayrak","year":"2009","unstructured":"Erbayrak M, Turkay C, Eraslan E, et al.: The role of fecal calprotectin in investigating inflammatory bowel diseases. Clinics (Sao Paulo) 2009, 64:421\u2013425.","journal-title":"Clinics (Sao Paulo)"},{"key":"145_CR24","doi-asserted-by":"crossref","unstructured":"\u2022 Diamanti A, Panetta F, Basso MS, et al.: Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay. Inflamm Bowel Dis 2010 (Epub ahead of print). This prospective study examines the diagnostic accuracy of calprotectin in children with gastrointestinal symptoms suggestive of IBD.","DOI":"10.1002\/ibd.21257"},{"key":"145_CR25","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ajg.2009.545","volume":"105","author":"AM Schoepfer","year":"2010","unstructured":"Schoepfer AM, Beglinger C, Straumann A, et al.: Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn\u2019s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010, 105:162\u2013169.","journal-title":"Am J Gastroenterol"},{"key":"145_CR26","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/j.1572-0241.2003.07458.x","volume":"98","author":"SV Kane","year":"2003","unstructured":"Kane SV, Sandborn WJ, Rufo PA, et al.: Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003, 98:1309\u20131314.","journal-title":"Am J Gastroenterol"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-010-0145-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-010-0145-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-010-0145-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T21:36:06Z","timestamp":1711834566000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-010-0145-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,2]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["145"],"URL":"https:\/\/doi.org\/10.1007\/s11894-010-0145-9","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,2]]}}}